Wednesday, July 03, 2024 3:03:27 PM
Optune isn't covered because it doesn't actually work. Don't take my word for it, hear what Dr. LL and others have to say.
WRT to Dr. Ashkan, please tell me you're joking - you can't possibly be that ignorant, but apparently, you are so below is his bio info from King's NHS page:
insert-text-here
Prof Keyoumars Ashkan
Consultant Neurosurgeon
Year Qualified
1993
Qualifications
BA (Hons), BSc (Hons), Dip Mus, MB BCh (Commend), MD, MRCP (UK), FRCS (Eng.), FRCP, FRCPS (Glasg.), FRCPath, FRCS (SN)
Specialty
Neurosurgery
Special Interests
Functional neurosurgery
Neuro-oncology
Spinal surgery
Surgery for intractable pain and headaches
Biography
Prof Ashkan is Professor of Neurosurgery with specialist interest in functional neurosurgery, image guided surgery, and surgery for brain and spinal tumours. He is the lead for neuro-oncology and the lead for the neuroscience commercial clinical trial unit at King’s College Hospital. He was appointed as a consultant in 2004.
He trained at the University of Wales College of Medicine and underwent postgraduate training in both medicine and surgery. He then completed an intensive general neurosurgical training programme on the South Thames Specialist Registrar rotation, working in several leading units such as King’s College, Atkinson Morley’s and The National Hospitals. Following this, he spent a year of fellowship in France working with Prof Benabid, who is acknowledged as the founder of modern functional neurosurgery. Prior to his consultant appointment at King’s College Hospital Prof Ashkan was a Senior Lecturer in Functional Neurosurgery and Honorary Consultant Neurosurgeon at the Institute of Neurology and the National Hospital for Neurology and Neurosurgery.
Prof Ashkan is actively involved in research, especially in developing novel treatments for brain tumours and for Parkinson’s disease. He is the deputy lead for neurosciences Research Advisory Group at King’s College Hospital. He has published over 400 peer review papers, abstracts, and book chapters, and is a reviewer for several journals and grant awarding bodies. He is actively involved in training both undergraduate and postgraduate clinical and research students. He is a regular speaker at national and international neurosurgical scientific meetings.
Prof Ashkan is the President of the British Society for Stereotactic and Functional Neurosurgery, Chairman of the Surgical Group of the International Parkinson and Movement Disorder Society, and Lead for the Genomics England programme for brain tumours.
In 2018 he was voted Clinician of The Year by the Brain Tumour Charity.
WRT to Dr. Ashkan, please tell me you're joking - you can't possibly be that ignorant, but apparently, you are so below is his bio info from King's NHS page:
insert-text-here
Prof Keyoumars Ashkan
Consultant Neurosurgeon
Year Qualified
1993
Qualifications
BA (Hons), BSc (Hons), Dip Mus, MB BCh (Commend), MD, MRCP (UK), FRCS (Eng.), FRCP, FRCPS (Glasg.), FRCPath, FRCS (SN)
Specialty
Neurosurgery
Special Interests
Functional neurosurgery
Neuro-oncology
Spinal surgery
Surgery for intractable pain and headaches
Biography
Prof Ashkan is Professor of Neurosurgery with specialist interest in functional neurosurgery, image guided surgery, and surgery for brain and spinal tumours. He is the lead for neuro-oncology and the lead for the neuroscience commercial clinical trial unit at King’s College Hospital. He was appointed as a consultant in 2004.
He trained at the University of Wales College of Medicine and underwent postgraduate training in both medicine and surgery. He then completed an intensive general neurosurgical training programme on the South Thames Specialist Registrar rotation, working in several leading units such as King’s College, Atkinson Morley’s and The National Hospitals. Following this, he spent a year of fellowship in France working with Prof Benabid, who is acknowledged as the founder of modern functional neurosurgery. Prior to his consultant appointment at King’s College Hospital Prof Ashkan was a Senior Lecturer in Functional Neurosurgery and Honorary Consultant Neurosurgeon at the Institute of Neurology and the National Hospital for Neurology and Neurosurgery.
Prof Ashkan is actively involved in research, especially in developing novel treatments for brain tumours and for Parkinson’s disease. He is the deputy lead for neurosciences Research Advisory Group at King’s College Hospital. He has published over 400 peer review papers, abstracts, and book chapters, and is a reviewer for several journals and grant awarding bodies. He is actively involved in training both undergraduate and postgraduate clinical and research students. He is a regular speaker at national and international neurosurgical scientific meetings.
Prof Ashkan is the President of the British Society for Stereotactic and Functional Neurosurgery, Chairman of the Surgical Group of the International Parkinson and Movement Disorder Society, and Lead for the Genomics England programme for brain tumours.
In 2018 he was voted Clinician of The Year by the Brain Tumour Charity.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
